MetaCap

Veracyte Inc. (VCYT)

NASDAQ: VCYTHealth CareMedical SpecialitiesUSD

25.13+0.09 (+0.36%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

VCYT stock chart

Technical analysis

Key statistics

All statistics
52-week range
21.91 – 60.91
Day range
24.53 – 25.60
Volume / Avg
2.79M / 1.89M
Beta
—

52-week range

$21.91$60.91

VCYT stock today

On Nov 20, VCYT ended the session at $25.13, adding $0.09 (0.36%), versus the S&P 500's 3.70% decline. At this level, VCYT sits near the bottom of its 52-week range of $21.91 to $60.91: 58.7% below the high, set on Jun 30, 2026 and 14.7% above the low. VCYT is down 40.3% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 42.9%.

At 16.3x trailing earnings, Veracyte trades below the peer-group median of 51.9x. Its forward P/E of 16.2x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About Veracyte

Company profile

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis.

Industry
Medical Specialities
CEO
Mr. Marc A. Stapley
Headquarters
South San Francisco, CA
Employees
755
IPO year
2013

Financial highlights

Full financials

In fiscal 2025, Veracyte generated $517.1 million in revenue, up 16.0% from fiscal 2024, its 5th consecutive year of revenue growth. Net income was $66.4 million (+174.9% year over year), for a net margin of 12.8% versus a median of -20.6% in the prior 5 years. Gross margin was 70.1% (up from 66.9%) and operating margin 11.2%.

Veracyte annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$517.14M$445.76M$361.05M$296.54M$219.51M
Growth+16.01%+23.46%+21.76%+35.09%+86.85%
Net income$66.35M$24.14M$-74.40M$-36.56M$-75.56M
EPS (diluted)$0.82$0.31$-1.02$-0.51$-1.11

Analyst forecast

Forecast

Consensus (12 analysts)

buy

Avg. price target

$44.60+77.48%

  • Strong buy 2
  • Buy 7
  • Hold 3
  • Sell 0
  • Strong sell 0

Target range

Low $30.00High $65.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 4, 2026
EPS actual vs est.
$0.38 vs $0.29
Surprise
+31.03%

VCYT news

All VCYT news

Veracyte peers

Health Care sector
VCYT peer companies
CompanyPrice% ChgMarket capCompare
CLOVClover Health Investments Corp. Class A3.73-1.06%$2.00Bvs VCYT
FTREFortrea Holdings Inc.18.55-7.94%$1.79Bvs VCYT
PSNLPersonalis Inc.14.27-3.06%$1.55Bvs VCYT
TRUPTrupanion Inc.35.56-0.86%$1.54Bvs VCYT
CELCCelcuity Inc.53.35-5.26%$2.61Bvs VCYT
LMRILumexa Imaging Holdings Inc.14.26+1.42%$1.37Bvs VCYT
ALHCAlignment Healthcare Inc.6.37-2.00%$1.33Bvs VCYT
FRNMFreenome Inc.9.36-5.69%$1.04Bvs VCYT

Indexes, lists and sector

Veracyte stock FAQ

What is Veracyte's stock price today?

VCYT last traded at $25.13 as of Nov 20, 4:00 PM EST, up 0.36% on the day. Prices are delayed at least 15 minutes.

What is VCYT's P/E ratio?

VCYT trades at a trailing P/E ratio of 16.32 and a forward P/E of 16.15, compared with a median of 51.9 for its closest peers.

Who is Veracyte's CEO?

Mr. Marc A. Stapley is the chief executive officer of Veracyte Inc., which has about 755 employees.

What is the VCYT 52-week high?

The 52-week high for VCYT is $60.91 and the 52-week low is $21.91. The stock is currently 58.7% below its high.

Compare VCYT